Manufacturers: 4D Molecular Therapeutics
4D-150 is an investigational gene therapy developed by 4D Molecular Therapeutics (4DMT) for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). It is designed as a potential backbone therapy providing multi-year, sustained delivery of anti-VEGF biologics, utilizing a novel R100 vector and a dual transgene payload. Two-year results from the phase 2b PRISM trial showed durable treatment-burden reduction with 4D-150 in wet AMD, sustaining vision while cutting anti-VEGF injections by up to 87%.
4D-150 is an investigational gene therapy developed by 4D Molecular Therapeutics (4DMT) for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). It is designed as a potential backbone therapy providing multi-year, sustained delivery of anti-VEGF biologics, utilizing a novel R100 vector and a dual transgene payload. Two-year results from the phase 2b PRISM trial showed durable treatment-burden reduction with 4D-150 in wet AMD, sustaining vision while cutting anti-VEGF injections by up to 87%.
2 associated conditions
